Dashboard
Manage Tickers

SYRE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

dominos-pizza-posts-upbeat-results-joins-astria-therapeutics-albertsons-companies-polaris-and-other-big-stocks-moving-higher-on-tuesday
Domino's Pizza Posts Upbeat Results, Joins...
10/14/2025 14:15:51

Core News & Articles
Reported Earlier, Spyre Therapeutics Price...
10/14/2025 04:59:41

Core News & Articles
Spyre Therapeutics Reveals Proposed Public...
10/13/2025 20:03:00

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:S...

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/10/2025 21:06:24

Core News & Articles
Reported Sunday, Spyre Therapeutics Unveil...
10/06/2025 06:33:36

this-united-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This United Therapeutics Analyst Begins Co...
09/26/2025 12:03:22

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Core News & Articles
Deutsche Bank Initiates Coverage On Spyre ...
09/26/2025 11:38:09

Deutsche Bank analyst David Hoang initiates coverage on Spyre Therapeutics (NASDAQ: SYRE) with a Buy rating and announces Pr...

Core News & Articles
BTIG Reiterates Buy on Spyre Therapeutics,...
09/16/2025 10:43:02

BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $70 price target.

Core News & Articles
Spyre Therapeutics Doses First Patient In ...
09/15/2025 12:02:29

Spyre Therapeutics, Inc.

Core News & Articles
Spyre Therapeutics Q2 EPS $(0.49) Beats $(...
08/05/2025 20:39:34

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(...

Core News & Articles
Spyre Therapeutics Announces Interim Phase...
06/17/2025 11:32:35

Core News & Articles
Spyre Therapeutics To Announce Interim Pha...
06/16/2025 20:10:49

Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, do...

Core News & Articles
Spyre Therapeutics Q1 EPS $(0.62) Beats $(...
05/08/2025 21:16:51

Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(...

Core News & Articles
This Weyerhaeuser Analyst Begins Coverage ...
04/08/2025 12:53:59

Core News & Articles
Leerink Partners Initiates Coverage On Spy...
04/08/2025 11:56:32

Leerink Partners analyst Faisal Khurshid initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Outperform rating and...

Core News & Articles
Spyre Therapeutics Announces First Partici...
03/27/2025 20:11:42

Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opport...

Core News & Articles
Spyre Therapeutics Q4 2024 GAAP EPS $(0.81...
02/27/2025 21:41:09

Core News & Articles
Spyre Files For $500 Mixed Shelf Offering
02/27/2025 21:39:21

-SEC Filing

Core News & Articles
Spyre Therapeutics Anticipates Cash Runway...
01/13/2025 13:23:20

Core News & Articles
Spyre Therapeutics Added To The Nasdaq Bio...
12/18/2024 13:18:25

Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, ra...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION